Table 1.
Groups |
CM Apoptosis |
CM hypertrophy (CSA, μm2) |
Myocardial fibrosis (% of area) |
||
---|---|---|---|---|---|
TUNEL-positive CM | Area (mm2) | TUNEL-positive CM (mm−2 × 10−3) | |||
Progression of heart failure | |||||
Shams (n=9) |
0.6±0.2 |
116±7 |
5±2 |
251±15 |
7±1 |
1wkHF (n=6) |
1.8±0.8 |
127±18 |
16±6 |
282±12 |
8±1 |
2wksHF (n=7) |
2.1±0.3 |
118±11 |
18±3 |
295±12 |
13±1 |
3wksHF (n=8) |
7.5±1.6* |
139±18 |
50±10* |
317±17* |
19±2* |
| |||||
Sabiporide treatment | |||||
Shams+3wksSABI (n=7) |
1.4±0.5 |
175±5 |
9±3 |
227±11 |
5±1 |
3wksHF+2wksSABI (n=7) |
2.6±1.1 |
117±9 |
21±9*,# |
257±13# |
16±1*,# |
3wksHF+3wksSABI (n=9) | 5.8±1.3* | 169±16 | 35±6*,# | 294±9*,# | 12±1# |
Area=total analyzed surface area; CM=cardiomyocyte; CSA=cross-sectional area; HF=heart failure; SABI=sabiporide.
Values are Means±s.e.m. with *P<0.05 vs Shams and #P<0.05 vs 3wksHF.